Abstract
Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (Ctrough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/μ1 and 5.2/μ1, respectively. Cases had a significantly higher C1/F/kg if compared with controls (0.269 ± 0.12 versus 0.167 ± 0.05 L/h/kg, p 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.
| Original language | English |
|---|---|
| Pages (from-to) | 349-353 |
| Number of pages | 5 |
| Journal | Current HIV Research |
| Volume | 5 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - May 2007 |
Fingerprint
Keywords
- Efavirenz
- HIV infection
- Pharmacokinetic interaction
- Rifampicin
ASJC Scopus subject areas
- Infectious Diseases
Cite this
Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients. / Matteelli, Alberto; Regazzi, Mario; Villani, Paola; De Iaco, Giuseppina; Cusato, Maria; Carvalho, Anna Cristina C; Caligaris, Silvio; Tomasoni, Lina; Manfrin, Maria; Capone, Susanna; Carosi, Giampiero.
In: Current HIV Research, Vol. 5, No. 3, 05.2007, p. 349-353.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multiple-dose pharmacokinetics of Efavirenz with and without the use of Rifampicin in HIV-positive patients
AU - Matteelli, Alberto
AU - Regazzi, Mario
AU - Villani, Paola
AU - De Iaco, Giuseppina
AU - Cusato, Maria
AU - Carvalho, Anna Cristina C
AU - Caligaris, Silvio
AU - Tomasoni, Lina
AU - Manfrin, Maria
AU - Capone, Susanna
AU - Carosi, Giampiero
PY - 2007/5
Y1 - 2007/5
N2 - Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (Ctrough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/μ1 and 5.2/μ1, respectively. Cases had a significantly higher C1/F/kg if compared with controls (0.269 ± 0.12 versus 0.167 ± 0.05 L/h/kg, p 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.
AB - Rifampicin (RIF) decreases serum concentrations of several antiretroviral drugs. We carried out a prospective, comparative study to define efavirenz (EFV) pharmacokinetics in 16 cases and 13 controls. Cases were HIV and tuberculosis (TB) co-infected adults assuming RIF 600 mg once daily and EFV 800 mg once daily. Patients on EFV at standard 600 mg dose without RIF were taken as controls. EFV levels in plasma were assayed by high-performance liquid chromatography (HLPC) predose (Ctrough) and at 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 16, 18, 22 and 24 hours post-dose, and pharmacokinetic parameters were determined by non-compartmental methods. Among cases, 81% were males, mean age was 37 years, 50% were Caucasians, mean weight was 64 kg, mean CD4 cell counts and log HIV RNA copies were 160/μ1 and 5.2/μ1, respectively. Cases had a significantly higher C1/F/kg if compared with controls (0.269 ± 0.12 versus 0.167 ± 0.05 L/h/kg, p 60 kg in Europe. Therapeutic drug monitoring may be beneficial for patients on combination therapy with RIF.
KW - Efavirenz
KW - HIV infection
KW - Pharmacokinetic interaction
KW - Rifampicin
UR - http://www.scopus.com/inward/record.url?scp=34249069242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249069242&partnerID=8YFLogxK
U2 - 10.2174/157016207780636588
DO - 10.2174/157016207780636588
M3 - Article
VL - 5
SP - 349
EP - 353
JO - Current HIV Research
JF - Current HIV Research
SN - 1570-162X
IS - 3
ER -